Co­manche se­cures $75M to test preeclamp­sia siR­NA in PhII, adds Scott Got­tlieb to board

Co­manche Bio­phar­ma, an siR­NA biotech cre­at­ed by vet­er­ans of The Med­i­cines Com­pa­ny, has reeled in a $75 mil­lion Se­ries B to test its drug can­di­date for preeclamp­sia, a preg­nan­cy com­pli­ca­tion that im­pacts mil­lions of women each year.

The Con­cord, MA-based biotech al­so said for­mer FDA Com­mis­sion­er Scott Got­tlieb has joined its board in con­junc­tion with an­nounc­ing the over­sub­scribed round from New En­ter­prise As­so­ciates (NEA), At­las Ven­ture, GV, F-Prime Cap­i­tal, Lil­ly Asia Ven­tures and Longview Health­care Ven­tures. Got­tlieb, a part­ner at NEA, will be joined on the board by At­las part­ner David Grayzel, the com­pa­ny said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER